High-fidelity PAMless base editing of hematopoietic stem cells to treat chronic granulomatous disease
Authors:
- Vera BzhilyanskayaVBVera Bzhilyanskaya
- Linyuan MaLMLinyuan Ma
- Lauren R. FoxLFLauren R. Fox
- Madelynn N. WhittakerMWMadelynn N. Whittaker
- Ronald J. MeisRMRonald J. Meis
- Amanda LawsonALAmanda Lawson
- Michelle MaMMMichelle Ma
- Narda TheobaldNTNarda Theobald
- Sandra BurkettSBSandra Burkett
- Colin L. SweeneyCSColin L. Sweeney
- 16 October 2024
- journal article
- research article
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 16 (769) , eadj6779
Abstract
X-linked chronic granulomatous disease (X-CGD) is an inborn error of immunity (IEI) resulting from genetic mutations in the cytochrome b-245 beta chain ( CYBB ) gene. The applicability of base editors (BEs) to correct mutations that cause X-CGD is constrained by the requirement of Cas enzymes to recognize specific protospacer adjacent motifs (PAMs). Our recently engineered PAMless Cas enzyme, SpRY, can overcome the PAM limitation. However, the efficiency, specificity, and applicability of SpRY-based BEs to correct mutations in human hematopoietic stem and progenitor cells (HSPCs) have not been thoroughly examined. Here, we demonstrated that the adenine BE ABE8e-SpRY can access a range of target sites in HSPCs to correct mutations causative of X-CGD. For the prototypical X-CGD mutation CYBB c.676C>T, ABE8e-SpRY achieved up to 70% correction, reaching efficiencies greater than three-and-one-half times higher than previous CRISPR nuclease and donor template approaches. We profiled potential off-target DNA edits, transcriptome-wide RNA edits, and chromosomal perturbations in base-edited HSPCs, which together revealed minimal off-target or bystander edits. Edited alleles persisted after transplantation of the base-edited HSPCs into immunodeficient mice. Together, these investigational new drug–enabling studies demonstrated efficient and precise correction of an X-CGD mutation with PAMless BEs, supporting a first-in-human clinical trial (NCT06325709) and providing a potential blueprint for treatment of other IEI mutations.Keywords
This publication has 84 references indexed in Scilit:
- Base Editing of Human Hematopoietic Stem Cells2023
- Making the cut with PAMless CRISPR-Cas enzymesTrends in Genetics, 2021
- Off-target effects of base editors: what we know and how we can reduce itCurrent Genetics, 2021
- UM171-Expanded Cord Blood Transplants Support Robust T Cell Reconstitution with Low Rates of Severe InfectionsTransplantation and Cellular Therapy, 2021
- Lentiviral gene therapy corrects platelet phenotype and function in patients with Wiskott-Aldrich syndromeJournal of Allergy and Clinical Immunology, 2019
- Lentiviral haemopoietic stem/progenitor cell gene therapy for treatment of Wiskott-Aldrich syndrome: interim results of a non-randomised, open-label, phase 1/2 clinical studyThe Lancet Haematology, 2019
- Hematopoietic Stem Cell Quiescence Promotes Error-Prone DNA Repair and MutagenesisCell Stem Cell, 2010
- Thymic lymphoproliferative disease after successful correction of CD40 ligand deficiency by gene transfer in miceNature Medicine, 1998
- Degenerate oligonucleotide-primed PCR: General amplification of target DNA by a single degenerate primerGenomics, 1992
- Cytogenetic analysis by chromosome painting using dop‐pcr amplified flow‐sorted chromosomesGenes, Chromosomes and Cancer, 1992